{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:23Z","timestamp":1791932363598,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2020.10.072","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:08:07Z","timestamp":1604700487000},"page":"3050-3052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG)"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-8367","authenticated-orcid":false,"given":"Robert T.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-5691","authenticated-orcid":false,"given":"Sonali","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Condit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.072_b0010","unstructured":"Vaccine Centre, London school of hygiene & tropical medicine. COVID-19 vaccine development pipeline. Accessed on 16 October 2020 at https:\/\/vac-lshtm.shinyapps.io\/ncov_vaccine_landscape\/."},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.072_b0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(20)30426-6","article-title":"A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation","volume":"20","author":"COCONEL Group","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.072_b0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12961-020-00571-3","article-title":"From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?","volume":"18","author":"Hanney","year":"2020","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.vaccine.2020.10.072_b0025","series-title":"Industry risk communication manual: Improving dialogue with communities","author":"Hance","year":"1990"},{"key":"10.1016\/j.vaccine.2020.10.072_b0030","doi-asserted-by":"crossref","unstructured":"Wunderlich S, Gatto KA. Consumer perception of genetically modified organisms and sources of information. Adv Nutr. 2015;6(6):842\u2013851. Published 2015 Nov 13. doi:10.3945\/an.115.008870","DOI":"10.3945\/an.115.008870"},{"key":"10.1016\/j.vaccine.2020.10.072_b0035","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1016\/j.vaccine.2020.06.017","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0040","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1016\/j.vaccine.2020.06.044","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines","volume":"38","author":"Kochhar","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.08.009","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines","author":"Condit","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0050","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines","author":"Kochhar","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.09.042","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of live attenuated viral vaccines","author":"Gurwith","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0060","doi-asserted-by":"crossref","unstructured":"Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002; 21(3-4):298\u2013302. PubMed PMID: 12450705. doi.org\/10.1016\/S0264-410X(02)00449-8","DOI":"10.1016\/S0264-410X(02)00449-8"},{"issue":"9653","key":"10.1016\/j.vaccine.2020.10.072_b0065","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.072_b0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton collaboration viral vector vaccines safety working group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0075","unstructured":"World Health Organization (WHO) Informal Consultation on Characterization and Quality Aspect of Vaccines Based on Live Viral Vectors, WHO HQ, Geneva, 4-5 December, 2003, https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2020\/07\/WHO.viral-vectors-report-full.2003.pdf; [Accessed Oct. 16, 2020]."},{"issue":"51","key":"10.1016\/j.vaccine.2020.10.072_b0080","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1016\/j.vaccine.2016.02.015","article-title":"Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis","volume":"34","author":"Klug","year":"2016","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2020.10.072_b0085","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2020.10.072_b0090","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.08.085","article-title":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines","volume":"37","author":"Kochhar","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.072_b0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","article-title":"Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0105","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1517\/14712598.2012.704908","article-title":"Clinical development of IMOJEV (R) \u2013 a recombinant Japanese encephalitis chimeric vaccine (JE-CV)","volume":"12","author":"Appaiahgari","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2020.10.072_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"51","key":"10.1016\/j.vaccine.2020.10.072_b0115","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"issue":"10068","key":"10.1016\/j.vaccine.2020.10.072_b0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.10.072_b0130","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety, 5\u20136 June 2019: Safety of Ebola virus vaccines. Wkly Epidem Rec 2019; 94:310\u20132."},{"key":"10.1016\/j.vaccine.2020.10.072_b0135","doi-asserted-by":"crossref","unstructured":"Custers J, Kim D, Leyssen M, Gurwith Mc, Tomaka F, Robertson JS, et al. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk\/benefit assessment. Vaccine 2020 (in press).","DOI":"10.1016\/j.vaccine.2020.09.018"},{"key":"10.1016\/j.vaccine.2020.10.072_b0140","article-title":"The Brighton Collaboration Standardized template for collection of key information for risk\/benefit assessment of Modified Vaccinia Ankara (MVA) vaccine","author":"Volkmann","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.072_b0145","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety, 4\u20135 December 2019: Ad26.ZEBOV\/MVA-BN-Filo vaccine. Wkly Epidem Rec 2020; 95:28\u201330."},{"key":"10.1016\/j.vaccine.2020.10.072_b0150","unstructured":"World Health Organization. Global advisory committee on vaccine safety, 27\u201328 May 2020: Conclusion and recommendations. Wkly Epidem Rec 2020; 95:336."},{"key":"10.1016\/j.vaccine.2020.10.072_bib151","doi-asserted-by":"crossref","unstructured":"Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 Vaccine Development: Current Status. Mayo Clin Proc. 2020 Oct;95(10):2172-2188. doi: 10.1016\/j.mayocp.2020.07.021. Epub 2020 Jul 30. PMID: 33012348; PMCID: PMC7392072.","DOI":"10.1016\/j.mayocp.2020.07.021"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2031392X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2031392X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:34Z","timestamp":1759402594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2031392X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X2031392X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.044","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.028","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.042","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}